Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
Stocks · News reference
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug
Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing durable safety profile and clinical improvements compared to natural history data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share
8-K filing — Larimar Therapeutics, Inc. (LRMR)
Filed: 2026-08-04 AccNo: 0001193125-26-331516 Size: 19 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10